• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • LANSO TEVA 30 mg
    / Teva Israel LTD, Israel


    Active Ingredient
    Lansoprazole 30 mg

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Gastro-resistant hard capsules

    28 x 30 mg

    not in the basket chart 28889 12664

    Dosage

    Please refer to the license holder for further details.


    Indications

    * Treatment of duodenal and gastric ulcer
    * Treatment or prophylaxis of reflux oesophagitis
    * Eradication of Helicobacter pylori (H. pylori) concurrently given with appropriate antibiotic therapy for treatment of H.pylori-associated ulcers
    * Treatment of NSAID-associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment
    * Prophylaxis of NSAID-associated gastric ulcers and duodenal ulcers in patients at risk requiring continued therapy
    * Symptomatic gastroesophageal reflux disease
    * Zollinger-Ellison syndrome.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients. Please refer to the license holder for further details.


    Special Precautions

    Please refer to the license holder for further details.


    Side Effects

    Please refer to the license holder for further details.


    Drug interactions

    Please refer to the license holder for further details.


    Pregnancy and Lactation

    Please refer to the license holder for further details.


    Overdose

    Please refer to the license holder for further details.


    Manufacturer
    Teva Israel LTD, Israel
    CLOSE